Adam M Brufsky MD

PubMed

• Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank.
  Sean Khozin, Nancy A Dreyer, Dominic Galante, Raymond Liu, Peter Neumann
  Advances in Therapy. 2025-07-01
• Hope for OTHERS (Our Tissue Helping Enhance Research & Science): research results from the University of Pittsburgh rapid autopsy program for breast cancer.
  Alexander Chih-Chieh Chang, Marija Balic, Tanner Bartholow, Rohit Bhargava, Daniel D Brown
  Breast Cancer Research. 2025-06-19
• First-Line Camizestrant for Emerging-Mutated Advanced Breast Cancer.
  François-Clément Bidard, Erica L Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma
  The New England Journal of Medicine. 2025-06-01

Journal Articles

• Molecular Mechanisms Linking High Body Mass Index to Breast Cancer Etiology in Post-Menopausal Breast Tumor and Tumor-Adjacent Tissues  
  Adam M Brufsky, Tari A King, Susan B Brown, Breast Cancer Research and Treatment
• Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...  
  H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer  
  Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Lectures

• A Metastatic Breast Cancer Patient with Activating HER2 Exon 20 Insertion Mutation Responds to Poziotinib; A Case Report of Compassionate Drug Use 
  2019 ASCO Annual Meeting - 6/1/2019